HOXB3 and acute myeloid leukemia: ROC curve analysis indicated that HOXB3 methylation might act as a potential biomarker for distinguishing AML patients from controls, with an AUC of 0.651 (95% CI: 0.532-0.770, P = 0.047) (Figure 4b).